​

​

Exhibit 99.1

​

​

ReShape Lifesciences™ to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

​

Full Year Revenue Increased by Approximately 20%, from $11.3 M to $13.6 M

​

$22.8 M in Cash and Cash Equivalents as of December 31, 2021

​

Company Eliminated All Debt from Balance Sheet

​

Webcast to be Held at 5:30 pm ET on Monday, March 28, 2022

​

SAN CLEMENTE, Calif., March 17, 2022 -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the year-ended December 31, 2021, including a corporate update, on Monday, March 28, 2022, after-market. A conference call and webcast will be held at 5:30 pm ET.

​

“2021 was a transformative year for ReShape, punctuated by our listing on Nasdaq and the highly anticipated re-launch of the Lap-Band®,” stated Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences. “As a result of our efforts, 2021 revenues increased by 20%, to $13.6 million, we were able to eliminate all debt from our balance sheet including our final $3 million obligation to Apollo Endosurgery for the purchase of the Lap-Band in December of 2018, and our cash balance at year-end was approximately $23 million. In the latter half of the year, we also kicked-off our national, direct-to-consumer television and print marketing campaign and virtual media tour. The results have been very strong and encouraging, and we look forward to providing updated metrics, soon.”

​

To participate in the conference call, dial 1-877-280-7473 (US/Canada) or 1-707-287-9370 (international) and enter passcode 5376956. A live link to the webcast will be available on the “Events and Presentations” section of ReShape’s website at: https://ir.reshapelifesciences.com/events-and-presentations.

​

A replay will be available approximately two hours after the call, for one week. The replay number is 1-855-859-2056, conference ID 5376956. An archived replay will also be available at: https://ir.reshapelifesciences.com/events-and-presentations.

​

About ReShape Lifesciences™

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. For more information, please visit www.reshapelifesciences.com

​

​

CONTACTS:

Company Contact:

Thomas Stankovich

Chief Financial Officer

949-276-6042

ir@ReShapeLifesci.com              

​

Investor Relations Contact:

Rx Communications Group

Michael Miller

(917)-633-6086

mmiller@rxir.com